Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 280

1.

Human papilloma virus 16 E6 oncoprotein associated with p53 inactivation in colorectal cancer.

Chen TH, Huang CC, Yeh KT, Chang SH, Chang SW, Sung WW, Cheng YW, Lee H.

World J Gastroenterol. 2012 Aug 14;18(30):4051-8. doi: 10.3748/wjg.v18.i30.4051.

2.

Human papillomavirus 16/18 E6 oncoprotein is expressed in lung cancer and related with p53 inactivation.

Cheng YW, Wu MF, Wang J, Yeh KT, Goan YG, Chiou HL, Chen CY, Lee H.

Cancer Res. 2007 Nov 15;67(22):10686-93.

3.

Human telomerase reverse transcriptase activated by E6 oncoprotein is required for human papillomavirus-16/18-infected lung tumorigenesis.

Cheng YW, Wu TC, Chen CY, Chou MC, Ko JL, Lee H.

Clin Cancer Res. 2008 Nov 15;14(22):7173-9. doi: 10.1158/1078-0432.CCR-08-0850.

4.

HPV infection and p53 inactivation in pterygium.

Tsai YY, Chang CC, Chiang CC, Yeh KT, Chen PL, Chang CH, Chou MC, Lee H, Cheng YW.

Mol Vis. 2009 Jun 1;15:1092-7.

5.

Association of p53 codon 72 genotypes and clinical outcome in human papillomavirus-infected lung cancer patients.

Chen SP, Hsu NY, Wu JY, Chen CY, Chou MC, Lee H, Cheng YW.

Ann Thorac Surg. 2013 Apr;95(4):1196-203. doi: 10.1016/j.athoracsur.2012.12.059. Erratum in: Ann Thorac Surg. 2017 Apr;103(4):1363.

PMID:
23522190
6.
7.

Human papillomavirus does not have a causal role in colorectal carcinogenesis.

Lorenzon L, Mazzetta F, Pilozzi E, Uggeri G, Torrisi MR, Ferri M, Ziparo V, French D.

World J Gastroenterol. 2015 Jan 7;21(1):342-50. doi: 10.3748/wjg.v21.i1.342.

8.

Salivary mucoepidermoid carcinoma: demonstration of transcriptionally active human papillomavirus 16/18.

Isayeva T, Said-Al-Naief N, Ren Z, Li R, Gnepp D, Brandwein-Gensler M.

Head Neck Pathol. 2013 Jun;7(2):135-48. doi: 10.1007/s12105-012-0411-2. Epub 2012 Dec 12.

9.

Human Papillomavirus 16 Oncoprotein Expression Is Controlled by the Cellular Splicing Factor SRSF2 (SC35).

McFarlane M, MacDonald AI, Stevenson A, Graham SV.

J Virol. 2015 May;89(10):5276-87. doi: 10.1128/JVI.03434-14. Epub 2015 Feb 25.

10.

Comparative prognostic value of HPV16 E6 mRNA compared with in situ hybridization for human oropharyngeal squamous carcinoma.

Shi W, Kato H, Perez-Ordonez B, Pintilie M, Huang S, Hui A, O'Sullivan B, Waldron J, Cummings B, Kim J, Ringash J, Dawson LA, Gullane P, Siu L, Gillison M, Liu FF.

J Clin Oncol. 2009 Dec 20;27(36):6213-21. doi: 10.1200/JCO.2009.23.1670. Epub 2009 Nov 2.

PMID:
19884544
11.

Molecular analyses of unselected head and neck cancer cases demonstrates that human papillomavirus transcriptional activity is positively associated with survival and prognosis.

Masterson L, Winder DM, Ball SL, Vaughan K, Lehmann M, Scholtz LU, Sterling JC, Sudhoff HH, Goon PK.

BMC Cancer. 2016 Jun 13;16:367. doi: 10.1186/s12885-016-2398-7.

12.

Molecular genetic characterization of p53 mutated oropharyngeal squamous cell carcinoma cells transformed with human papillomavirus E6 and E7 oncogenes.

Oh JE, Kim JO, Shin JY, Zhang XH, Won HS, Chun SH, Jung CK, Park WS, Nam SW, Eun JW, Kang JH.

Int J Oncol. 2013 Aug;43(2):383-93. doi: 10.3892/ijo.2013.1953. Epub 2013 May 24.

13.

E6 and e7 gene silencing and transformed phenotype of human papillomavirus 16-positive oropharyngeal cancer cells.

Rampias T, Sasaki C, Weinberger P, Psyrri A.

J Natl Cancer Inst. 2009 Mar 18;101(6):412-23. doi: 10.1093/jnci/djp017. Epub 2009 Mar 10.

PMID:
19276448
14.

A single-codon mutation converts HPV16 E6 oncoprotein into a potential tumor suppressor, which induces p53-dependent senescence of HPV-positive HeLa cervical cancer cells.

Ristriani T, Fournane S, Orfanoudakis G, Travé G, Masson M.

Oncogene. 2009 Feb 5;28(5):762-72. doi: 10.1038/onc.2008.422. Epub 2008 Nov 17.

PMID:
19015633
15.

Genetic patterns in head and neck cancers that contain or lack transcriptionally active human papillomavirus.

Braakhuis BJ, Snijders PJ, Keune WJ, Meijer CJ, Ruijter-Schippers HJ, Leemans CR, Brakenhoff RH.

J Natl Cancer Inst. 2004 Jul 7;96(13):998-1006.

PMID:
15240783
16.
17.

[Human papillomavirus type 16 E6 oncogene and expression of P53, RB and PCNA in human cervical carcinoma].

Bian J, Yu X, Dong J, Zhao W, Zhou Y, Luan Y.

Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 1997 Sep;11(3):271-3. Chinese.

PMID:
15617346
18.

Reduced p21(WAF1/CIP1) via alteration of p53-DDX3 pathway is associated with poor relapse-free survival in early-stage human papillomavirus-associated lung cancer.

Wu DW, Liu WS, Wang J, Chen CY, Cheng YW, Lee H.

Clin Cancer Res. 2011 Apr 1;17(7):1895-905. doi: 10.1158/1078-0432.CCR-10-2316. Epub 2011 Feb 16. Erratum in: Clin Cancer Res. 2015 Feb 15;21(4):935.

19.

Validation of methods for oropharyngeal cancer HPV status determination in US cooperative group trials.

Jordan RC, Lingen MW, Perez-Ordonez B, He X, Pickard R, Koluder M, Jiang B, Wakely P, Xiao W, Gillison ML.

Am J Surg Pathol. 2012 Jul;36(7):945-54. doi: 10.1097/PAS.0b013e318253a2d1.

PMID:
22743284
20.

DDX3 loss by p53 inactivation promotes tumor malignancy via the MDM2/Slug/E-cadherin pathway and poor patient outcome in non-small-cell lung cancer.

Wu DW, Lee MC, Wang J, Chen CY, Cheng YW, Lee H.

Oncogene. 2014 Mar 20;33(12):1515-26. doi: 10.1038/onc.2013.107. Epub 2013 Apr 15.

PMID:
23584477

Supplemental Content

Support Center